521 related articles for article (PubMed ID: 24332516)
41. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids.
Prokosch V; Thanos S; Spaniol K; Stupp T
Graefes Arch Clin Exp Ophthalmol; 2011 Jan; 249(1):121-5. PubMed ID: 20886224
[TBL] [Abstract][Full Text] [Related]
42. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
[TBL] [Abstract][Full Text] [Related]
44. Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream.
Mirza B; De'Ambrosis B
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():16-8. PubMed ID: 14616806
[TBL] [Abstract][Full Text] [Related]
45. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma.
Rhodes LE; de Rie MA; Leifsdottir R; Yu RC; Bachmann I; Goulden V; Wong GA; Richard MA; Anstey A; Wolf P
Arch Dermatol; 2007 Sep; 143(9):1131-6. PubMed ID: 17875873
[TBL] [Abstract][Full Text] [Related]
46. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of treatment of superficial basal cell carcinoma: surgical excision vs. imiquimod 5% cream.
Vanaclocha F; Daudén E; Badía X; Guillén C; Conejo-Mir JS; Sainz de Los Terreros M; Hamel L; Llorens MA;
Br J Dermatol; 2007 Apr; 156(4):769-71. PubMed ID: 17263811
[No Abstract] [Full Text] [Related]
48. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial.
Brown VL; Atkins CL; Ghali L; Cerio R; Harwood CA; Proby CM
Arch Dermatol; 2005 Aug; 141(8):985-93. PubMed ID: 16103328
[TBL] [Abstract][Full Text] [Related]
49. Has imiquimod 5% cream a role in the management of recurrent basal cell carcinoma?
RUIZ-VILLAVERDE R; SANCHEZ-CANO D; BURKHARDT-PEREZ P; SINTES RN
Eur J Dermatol; 2009; 19(5):481-3. PubMed ID: 19527989
[TBL] [Abstract][Full Text] [Related]
50. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
[TBL] [Abstract][Full Text] [Related]
51. Imiquimod: in superficial basal cell carcinoma.
Oldfield V; Keating GM; Perry CM
Am J Clin Dermatol; 2005; 6(3):195-200; discussion 201-2. PubMed ID: 15943496
[TBL] [Abstract][Full Text] [Related]
52. Superficial basal cell carcinoma on face treated with 5% imiquimod cream.
Malhotra AK; Bansal A; Mridha AR; Khaitan BK; Verma KK
Indian J Dermatol Venereol Leprol; 2006; 72(5):373-5. PubMed ID: 17050935
[TBL] [Abstract][Full Text] [Related]
53. Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
Gowda S; Tillman DK; Fitzpatrick JE; Gaspari AA; Goldenberg G
J Cutan Pathol; 2009 Aug; 36(8):878-81. PubMed ID: 19586497
[TBL] [Abstract][Full Text] [Related]
54. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Maus J; Munzel U
Eur J Dermatol; 2008; 18(6):677-82. PubMed ID: 18955210
[TBL] [Abstract][Full Text] [Related]
55. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome.
Micali G; Lacarrubba F; Nasca MR; De Pasquale R
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():19-23. PubMed ID: 14616807
[TBL] [Abstract][Full Text] [Related]
56. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
[TBL] [Abstract][Full Text] [Related]
57. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial.
Roozeboom MH; Arits AHMM; Mosterd K; Sommer A; Essers BAB; de Rooij MJM; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
J Invest Dermatol; 2016 Aug; 136(8):1568-1574. PubMed ID: 27113429
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients.
Vidal D; Alomar A
Clin Exp Dermatol; 2004 May; 29(3):237-9. PubMed ID: 15115500
[TBL] [Abstract][Full Text] [Related]
59. Treatment of lentigo maligna with imiquimod before staged excision.
Cotter MA; McKenna JK; Bowen GM
Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
[TBL] [Abstract][Full Text] [Related]
60. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application.
Gaitanis G; Nomikos K; Vava E; Alexopoulos EC; Bassukas ID
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1427-31. PubMed ID: 19555364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
